The US Food and Drug Administration FDA has approved the Conformable Gore Tag thoracic endoprosthesis (Gore) as a minimally invasive treatment for patients suffering from thoracic aortic aneurysms (TAAs).
Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the Esprit drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries and iliac arteries that have resulted in claudication (leg pain upon walking).
Spectranetics announced six month interim results from the PATENT (Photo-ablation using the Turbo-Booster and excimer laser for in-stent restenosis treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis in the femoropopliteal artery in the leg.
Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the Esprit drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries and iliac arteries that have resulted in claudication (leg pain upon walking).
Endologix has announced enrolment of the first patient in the company’s US clinical trial to evaluate the Ventana fenestrated stent graft system for the endovascular repair of juxtarenal and pararenal abdominal aortic aneurysms.
On 21 November, the US Food and Drug Administration (FDA) gave 510(k) clearance to Aptus Endosystems for its EndoStapling system, which will be known as the HeliFX Aortic Securement System. According to the FDA this is the first system used to repair a failed aortic endograft.
Aptus Endosystems, a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), has announced the start of ANCHOR, a global, multicentre, prospective post-market registry, which will evaluate the use of the HeliFX Aortic Securement System in the treatment of abdominal aortic aneurysms.
On Monday, CX delegates heard early data on the multilayer stent. In the discussion it became apparent that MARS requires firm thrombosis in the multilayers and flow to occur into the branches. The indicator of success is the reduction of sac diameter and the consensus was not to use the device in ruptured aneurysms. It became clear that the many experts cautioned not to expect too much of the device and to restrict its use in those high-risk patients where there is no other option.
Trabajo presentado en el I Curso de Medicina Vascular de la SEACV. La Dra. Morata Barrado es miembro del Servicio de Angiología, Cirugía Vascular y Endovascular del Hospital Universitario de Guadalajara.
According to a single-center study published in the Journal of Vascular Surgery, mortality is significantly greater for females undergoing elective endovascular repair (EVAR) for abdominal aortic aneurysms (AAA) than for males (2012;55:906–913). The study also showed that colon ischemia, native arterial rupture, and type 1 endoleaks are more frequent in women than in men. Elective EVAR benefits men more than women, concluded Manish Mehta, MD, et al, from the Vascular Group at the Albany Medical Center in Albany, New York.
The Society for Vascular Surgery and the American Venous Forum have issued clinical practice guidelines for early thrombus removal strategies in acute deep venous thrombosis (DVT). The guidelines, which were drafted by Mark H. Meissner, MD, et al, were published April 2 online ahead of print in the Journal of Vascular Surgery.
An evaluation of the comparative effectiveness of carotid revascularization procedures stratified by Medicare age was published March 30 online ahead of print in the Journal of Vascular Surgery by Jeffrey Jim, MD, et al for the Society for Vascular Surgery (SVS) Outcomes Committee.
Medtronic, Inc. (Minneapolis, MN) announced that it will be commencing the IN.PACT Global superficial femoral artery (SFA) clinical study. The international, prospective, multicenter study will collect and assess safety and efficacy data on the company’s In.Pact Admiral paclitaxel drug-eluting balloon (DEB) for the treatment of atherosclerotic disease in the SFA and/or popliteal arteries.
Covidien (NYSE: COV), el proveedor líder global de productos para la salud, anunció hoy que los resultados del uso de su stent EverFlex™ realizados durante un año para la implantación del stent en la arteria femoral superficial (AFS) fueron presentados durante la Conferencia de International Symposium on Endovascular Therapy (Simposio Internacional de Terapias Endovasculares), (ISET, por sus siglas en inglés).
Los resultados del ensayo clínico semestral denominado PEPPER (Paclitaxel REleasing Balloon in Patients PresEnting with In-Stent Restenosis) [Balón de liberación de Paclitaxel en pacientes con reestenosis del stent] arrojaron una cantidad muy baja de revascularizaciones y ninguna muerte por motivos cardíacos, según el informe presentado hoy en la Facultad Estadounidense de Cardiología (ACC) por el profesor doctor Christoph Hehrlein del Centro Médico de la Universidad de Friburgo, Alemania, quien también es el investigador responsable de coordinar el estudio.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos